Organization | Rawalpindi Medical College, Pakistan

Rawalpindi Medical College, Pakistan Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2006

NCT00916461

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

National Coordinating Investigator, Rawalpindi Medical University, Pakistan | Rawalpindi Medical College

Active Ingredients

Drugs in Phase 4 Trials (4)

apixaban (eliquis) (1 trial)

lidocaine (xylocaine) (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

midazolam (versed) (1 trial)

Drugs in Phase 3 Trials (5)

celecoxib (celebrex) (1 trial)

minocycline (minocin) (2 trials)

tranexamic acid (cyklokapron) (2 trials)

venlafaxine (effexor) (1 trial)

vortioxetine (trintellix) (1 trial)

Drugs in Other Trials (1)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 3)

Bipolar Disorder (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Disease (Phase 3)

Mental Disorders (Phase 2)

Mood Disorders (Phase 3)

Psychotic Disorders (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 10